NDAINTRAVENOUSSOLUTION
Approved
Oct 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
19
Data completeness
4/8 — Partial
FERABRIGHT (ferumoxytol) by Novartis is field. Approved for brain cancer. First approved in 2025.
Drug data last refreshed 18h ago
Mechanism of Action
field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues on T1-weighted MRI. Disruption of the blood-brain barrier allows distribution of ferumoxytol into lesions such as neoplasms. Since…
Indications (1)
Clinical Trials (19)
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
Started Jan 2024
100 enrolled
Coronary Artery Calcification
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus
Started Nov 2023
320 enrolled
Heart Aneurysm
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Started Feb 2023
17 enrolled
GlioblastomaGlioblastoma Multiforme
Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging
Started Sep 2021
44 enrolled
Chronic Kidney Diseases
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
Started Jan 2021
83 enrolled
Pregnancy RelatedAnemia, Iron Deficiency
Worked on FERABRIGHT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.